Diamond Biofund Past Earnings Performance

Past criteria checks 0/6

Diamond Biofund's earnings have been declining at an average annual rate of -56%, while the Capital Markets industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 56.1% per year.

Key information

-56.0%

Earnings growth rate

-57.1%

EPS growth rate

Capital Markets Industry Growth	12.7%
Revenue growth rate	-56.1%
Return on equity	-14.0%
Net Margin	111.0%
Last Earnings Update	30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Diamond Biofund makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TWSE:6901 Revenue, expenses and earnings (TWD Millions)
Date	Revenue	Earnings	G+A Expenses
30 Sep 24	-1,407	-1,561	161
30 Jun 24	-1,905	-2,060	154
31 Mar 24	-3,220	-3,364	153
31 Dec 23	-2,440	-2,583	148
30 Sep 23	-3,684	-3,831	112
30 Jun 23	-1,104	-1,244	102
31 Mar 23	-1,943	-2,076	70
31 Dec 22	1,016	798	102
30 Sep 22	3,563	3,343	128
30 Jun 22	3,756	3,555	91
31 Mar 22	6,015	5,762	112
31 Dec 21	3,064	2,852	64
31 Dec 20	6,501	6,090	404
31 Dec 19	-303	-371	64

Quality Earnings: 6901 is currently unprofitable.

Growing Profit Margin: 6901 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 6901 is unprofitable, and losses have increased over the past 5 years at a rate of 56% per year.

Accelerating Growth: Unable to compare 6901's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6901 is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (22.4%).

Return on Equity

High ROE: 6901 has a negative Return on Equity (-14.03%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 11:51
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Diamond Biofund Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution